FGFR3 and BORA

Data Source:
BioGRID (two hybrid)
HPRD (two hybrid)

		FGFR3	BORA
Description		fibroblast growth factor receptor 3	BORA aurora kinase A activator
Image			No pdb structure
GO Annotations	Cellular Component	Extracellular Region Nucleus Endoplasmic Reticulum Golgi Apparatus Plasma Membrane Integral Component Of Plasma Membrane Focal Adhesion Cell Surface Transport Vesicle Receptor Complex	Nucleus Cytoplasm Cytosol
	Molecular Function	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Fibroblast Growth Factor-activated Receptor Activity Protein Binding ATP Binding Fibroblast Growth Factor Binding Identical Protein Binding	Protein Binding Protein Kinase Binding
	Biological Process	MAPK Cascade Skeletal System Development Endochondral Ossification Chondrocyte Differentiation Endochondral Bone Growth Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Cell-cell Signaling Multicellular Organism Development Positive Regulation Of Cell Population Proliferation Fibroblast Growth Factor Receptor Signaling Pathway Positive Regulation Of Phospholipase Activity Peptidyl-tyrosine Phosphorylation Bone Mineralization Positive Regulation Of Kinase Activity Chondrocyte Proliferation Positive Regulation Of Tyrosine Phosphorylation Of STAT Protein Positive Regulation Of MAPK Cascade Positive Regulation Of Phosphatidylinositol 3-kinase Activity Protein Autophosphorylation Negative Regulation Of Developmental Growth Positive Regulation Of Protein Kinase B Signaling Bone Morphogenesis Positive Regulation Of ERK1 And ERK2 Cascade Bone Maturation Fibroblast Growth Factor Receptor Apoptotic Signaling Pathway	G2/M Transition Of Mitotic Cell Cycle Regulation Of Mitotic Nuclear Division Activation Of Protein Kinase Activity Regulation Of Protein Localization Cell Division Regulation Of Mitotic Spindle Organization
Pathways		Signaling by activated point mutants of FGFR3 FGFR3 mutant receptor activation t(4;14) translocations of FGFR3 Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer	Regulation of PLK1 Activity at G2/M Transition
Drugs		XL999 Pazopanib Ponatinib Lenvatinib Nintedanib Fostamatinib Erdafitinib Pemigatinib Selpercatinib
Diseases		Bladder cancer Multiple myeloma Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) CATSHL syndrome
GWAS		Bladder cancer ( 24163127 20972438) Blood protein levels ( 30072576) Metabolite levels ( 23823483) Urinary bladder cancer ( 20348956)	Mean reticulocyte volume ( 32888494)
Interacting Genes		43 interacting genes: ANOS1 ARAP1 ATF3 BORA C6orf47 CCDC17 CEP126 CHGB CTSK EPHA4 ERBB2 FGF1 FGF17 FGF18 FGF2 FGF23 FGF3 FGF4 FGF5 FGF6 FGF7 FGF8 FGF9 GPSM3 GRB2 GTF3C1 HBZ HNRNPL KRT8 NDUFS6 NECTIN1 POLA2 PTK2B RADIL RNF130 RPL8 RPS6KA3 SH2B1 SLC25A6 SMG7 SRPK2 STAT1 STAT3	4 interacting genes: AURKA BTRC FEZ1 FGFR3
Entrez ID		2261	79866
HPRD ID		00624	13389
Ensembl ID		ENSG00000068078	ENSG00000136122
Uniprot IDs		P22607 Q0IJ44	A0A087WV86 B5LMG6 Q6PGQ7
PDB IDs		1RY7 2LZL 4K33 6LVM 6PNX
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?